Login to Your Account

FDA Panel Holds out Hope to pNET Patients

By Mari Serebrov

Wednesday, April 13, 2011
SILVER SPRING, MD – Hope overrode the FDA's concerns about clinical trial conduct when an advisory committee gave a thumbs up Tuesday to Novartis Pharmaceuticals Corp.'s Afinitor and Pfizer Inc.'s Sutent as treatments for pancreatic neuroendocrine tumors (pNET).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription